65,437 trials
Hepatitis C
Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 81.3; 50.0 Percentage of participants…
Open-angle Glaucoma · Ocular Hypertension
Primary: Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline) — 14.8; -1.09 mmHg
Hypersomnia · Idiopathic Hypersomnia · Narcolepsy
Primary: Psychomotor Vigilance Task (PVT) Reaction Time — 279.1; 311.6; 333.8 Msec — p=0.47
Breast Cancer · Neoplasm Metastasis
Primary: Optimal Dose of RAD001 in Combination With Trastuzumab (Phase I) — 10 mg
Cesarean Section
Primary: Post Operative Pain — 2.56; 2.90 units on a scale
Hypertension
Primary: Systolic Blood Pressure After 4 Weeks — 158.3; 138.9 mmHg
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Hypertension
Primary: Systolic Blood Pressure After 4 Weeks — 140; 149 mmHg
Coronary Artery Disease
Primary: Angiographic In-Stent Late Lumen Loss — 0.09 mm
Type 2 Diabetes Mellitus · Hospitalization · Hyperglycemia
Primary: Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy — 209; 203; 225; 168.4 mg/dl
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Area Under the Concentration vs. Time Curve (AUC) — 250.25 IU*h/mL
Intravitreous · Injections
Primary: Positive Culture — 8 percentage of patients
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in the 24-hour Weighted Mean Glucose (WMG) — 11.0; -4.4 mg/dL — p=0.083
Influenza
Primary: Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV — 209; 187; 199; 548 Titers